Bausch + Lomb Corp (BLCO)

Currency in USD
17.16
+0.61(+3.69%)
Closed·
17.13-0.03(-0.17%)
·
BLCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.5417.25
52 wk Range
13.0918.92
Key Statistics
Prev. Close
16.55
Open
16.78
Day's Range
16.54-17.25
52 wk Range
13.09-18.92
Volume
493.85K
Average Volume (3m)
444.05K
1-Year Change
23.6311%
Book Value / Share
18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLCO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.88
Upside
+4.17%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

Bausch + Lomb Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
7 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.88
(+4.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy21.00+22.38%-MaintainJun 05, 2026
BofA Securities
Sell16.00-6.76%15.00MaintainApr 30, 2026
Evercore ISI
Hold16.00-6.76%17.00MaintainApr 29, 2026
Evercore ISI
Hold17.00-0.93%17.50MaintainApr 06, 2026
RBC Capital
Buy21.00+22.38%-MaintainMar 17, 2026

Bausch + Lomb Corp SWOT Analysis


Ophthalmology Leade
Bausch + Lomb, a $5.01B market cap company, dominates ophthalmology with diverse eye health products, facing spin-off uncertainties amid strong growth
Financial Resilience
Despite mixed performance, B+L shows resilience with 11% Q4 growth and 59.68% gross profit margin. Analysts project EPS of $0.50 for FY2025
Market Dynamics
Explore B+L's strategic positioning in the competitive ophthalmology market, with focus on innovative Dry Eye Disease treatments and new product launches
Future Prospects
Delve into B+L's growth strategy, aiming for 5.5-7.5% expansion in 2025. Analyst targets range from $12 to $22, reflecting varied market outlooks
Read full SWOT analysis

Bausch + Lomb Corp Earnings Call Summary for Q1/2026

  • Bausch + Lomb Q1 2026 EPS of $0.08 beat forecast of $0.05 by 60%; revenue reached $1.24B, up 6% YoY, exceeding expectations of $1.22B
  • Adjusted EBITDA surged 59% YoY to $200M; adjusted gross margin expanded 170 bps to 61.2%, driven by operational efficiency improvements
  • Strong performance across Vision Care, Surgical, and Pharmaceutical segments; company launched new products and advanced pipeline development
  • Stock declined 1.01% to $15.72 in pre-market despite earnings beat, potentially reflecting broader market trends and economic uncertainties
  • Management projects continued EPS and revenue growth; CEO Papa cited strong execution of strategic initiatives and resilient business model
Last Updated: 2026-04-29, 09:34 a/m
Read Full Transcript

Earnings

Latest Release
Apr 29, 2026
EPS / Forecast
0.08 / 0.05
Revenue / Forecast
1.24B / 1.22B
EPS Revisions
Last 90 days

BLCO Income Statement

Compare BLCO to Peers and Sector

Metrics to compare
BLCO
Peers
Sector
Relationship
P/E Ratio
−27.9x3.7x−0.4x
PEG Ratio
−0.71−0.530.00
Price/Book
1.0x1.5x2.6x
Price / LTM Sales
1.2x2.2x3.0x
Upside (Analyst Target)
4.9%26.2%49.1%
Fair Value Upside
Unlock23.7%6.1%Unlock

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.04M0.57%35.08M
Other Institutional Investors
328.25M92.07%5.63B
Public Companies & Retail Investors
26.24M7.36%450.33M
Total
356.54M100.00%6.12B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bausch Health Companies Inc.87.07%310,449,6435,327,316
Deutsche Bank Aktiengesellschaft0.99%3,528,44160,548

People Also Watch

173.06
ICLR
-1.14%
83.16
DBD
-0.20%
17.21
MNRO
+0.35%
2.280
BHR
+5.56%

FAQ

What Is the Bausch + Lomb (BLCO) Stock Price Today?

The Bausch + Lomb stock price today is 17.16 USD.

What Stock Exchange Does Bausch + Lomb Trade On?

Bausch + Lomb is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Bausch + Lomb?

The stock symbol for Bausch + Lomb is "BLCO."

What Is the Bausch + Lomb Market Cap?

As of today, Bausch + Lomb market cap is 6.12B USD.

What Is Bausch + Lomb's Earnings Per Share (TTM)?

The Bausch + Lomb EPS (TTM) is -0.62.

When Is the Next Bausch + Lomb Earnings Date?

Bausch + Lomb will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is BLCO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bausch + Lomb Stock Split?

Bausch + Lomb has split 0 times.

How Many Employees Does Bausch + Lomb Have?

Bausch + Lomb has 13000 employees.

What is the current trading status of Bausch + Lomb (BLCO)?

As of Jul 04, 2026, Bausch + Lomb (BLCO) is trading at a price of 17.16 USD, with a previous close of 16.55 USD. The stock has fluctuated within a day range of 16.54 USD to 17.25 USD, while its 52-week range spans from 13.09 USD to 18.92 USD.

What Is Bausch + Lomb (BLCO) Price Target According to Analysts?

The average 12-month price target for Bausch + Lomb is 17.88 USD, with a high estimate of 21 USD and a low estimate of 16 USD. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +4.17% Upside potential.

What Is the BLCO After Hours Price?

BLCO's last after hours stock price is 17.13 USD, the stock has decreased by -0.03, or -0.17%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.